Giardiasis is an intestinal protozoal infection caused by Giardia duodenalis (also called G. lamblia or G. intestinalis), transmitted via the fecal-oral route. It is the most common intestinal parasitic infection in the United States, with 15,000–20,000 reported cases annually. [1] Below is a clinically structured summary for emergency medicine and primary care.
1. History
- Key HPI questions: Onset, duration, and character of diarrhea (watery → greasy/fatty/foul-smelling over time); frequency of stools; presence of blood or mucus (typically absent in giardiasis) [1-2]
- Symptom characterization: Loose, foul-smelling, fatty, nonbloody stools; flatulence; bloating; abdominal cramping; nausea; anorexia; weight loss [1]
- Timing: Incubation period averages 7 days (range 1–2 weeks); symptoms self-limited over 2–6 weeks if untreated, but chronic giardiasis can wax and wane for months [1-2]
- Triggers/exposures: Recent travel to endemic areas, camping/backpacking with untreated water consumption, daycare exposure, swimming in recreational water, well water use, oral-anal sexual contact [1][3]
- Important negatives: Absence of bloody stools, absence of high fever (helps distinguish from invasive bacterial diarrhea) [2]
2. Alarm Features
- Severe dehydration (especially in children, elderly, immunocompromised)
- Significant weight loss (chronic giardiasis can cause up to 25 lb weight loss) [1]
- Failure to thrive or growth stunting in children [2][4]
- Signs of malnutrition or malabsorption (vitamin D deficiency, iron deficiency) [1][4]
- Biliary or pancreatic duct involvement (rare): RUQ pain, jaundice [1]
- Immunocompromised patients (HIV, transplant): prolonged/severe course, higher risk of complications [1-2]
3. Medications
First-line treatments: [1][5]
The following table from the AAFP summarizes treatment options and dosing for intestinal parasites including giardiasis:
- Contraindicated/cautions: Avoid alcohol with nitroimidazoles (disulfiram-like reaction); metronidazole and tinidazole should be used cautiously in first trimester of pregnancy [6]
- Pregnancy: Paromomycin (nonabsorbable aminoglycoside) is considered safest in pregnancy; defer treatment to second/third trimester when possible [1]
- Antimotility agents should be used with caution, especially in young children [2]
4. Diet
- Acute phase: Aggressive oral rehydration with electrolyte-containing solutions; bland, easily digestible foods; avoid dairy initially due to post-infectious lactose intolerance (occurs in 20–40% of patients) [2]
- Chronic phase: Monitor for malabsorption; nutritional supplementation may be needed (iron, vitamin D, micronutrients) [1][4]
- Hydration: Oral rehydration preferred when tolerated; IV fluids if unable to maintain oral intake or clinically dehydrated [2]
- Lactose intolerance may persist for several weeks after parasite clearance [2]
5. Review of Systems
- GI: Diarrhea character (watery vs. greasy/steatorrhea), bloating, flatulence, cramping, nausea, vomiting, anorexia, constipation (can alternate)
- Constitutional: Fatigue, malaise, weight loss, fever (usually low-grade if present)
- Dermatologic: Urticaria (uncommon but reported) [1]
- Musculoskeletal: Arthralgias (reactive arthritis is a recognized post-infectious complication) [2][7]
- Psychiatric: Depression, cognitive impairment (chronic infection in children) [1][7]
6. Collateral History and Family History
- Household contacts with similar symptoms (person-to-person transmission common)
- Daycare attendance or employment (high-risk setting for outbreaks) [1][3]
- Travel history to endemic regions with poor sanitation [3]
- Recreational water exposure (swimming pools, lakes, streams) [1]
- Occupation: food handlers require treatment even if asymptomatic [1]
- Sexual history: oral-anal contact is a risk factor [1]
- Pets/animal exposure (beavers, domestic animals as potential reservoirs) [8-9]
7. Risk Factors
- Children <5 years (most commonly reported age group) [1]
- Daycare settings or institutional living [1][3]
- Travel to areas with poor sanitation [3]
- Backpackers/campers drinking untreated surface water [1]
- Swimmers in contaminated recreational water [1]
- Shallow well water use (<25 ft) [1]
- Immunocompromised states (HIV, IgA deficiency, hypogammaglobulinemia) [1-2]
- Oral-anal sexual contact [1]
- Close contact with infected individuals or domestic/wild mammals [1][8]
8. Differential Diagnosis
- Cryptosporidiosis — watery diarrhea, similar exposure history; distinguished by acid-fast staining; more severe in immunocompromised [10]
- Cyclosporiasis — prolonged watery diarrhea, often foodborne (fresh produce); diagnosed by modified acid-fast stain or PCR [10]
- Amebiasis (E. histolytica) — can present with bloody/dysenteric stools (unlike Giardia); liver abscess possible [10]
- Irritable bowel syndrome — chronic giardiasis frequently misdiagnosed as IBS; waxing/waning symptoms, bloating, alternating bowel habits [1][11]
- Celiac disease — chronic diarrhea, steatorrhea, malabsorption, weight loss; serologic testing (tTG-IgA) helps distinguish [10]
- Inflammatory bowel disease — bloody diarrhea, systemic inflammation; endoscopy/biopsy for diagnosis
- Viral gastroenteritis — typically self-limited (<7 days); no steatorrhea
- Bacterial enteritis (Salmonella, Campylobacter, Shigella) — more acute onset, fever, bloody stools more common; stool culture positive [12]
- Small intestinal bacterial overgrowth (SIBO) — bloating, flatulence, steatorrhea; consider in chronic cases
- Lactose intolerance — can be primary or post-infectious; hydrogen breath test
9. Past Medical History
- Prior episodes of giardiasis or parasitic infections (reinfection common)
- Immunodeficiency states (HIV, common variable immunodeficiency, IgA deficiency)
- History of IBS or functional GI disorders (may mask chronic giardiasis) [1]
- Prior GI surgery or conditions affecting motility
- Chronic illnesses affecting immune function (transplant, malignancy, immunosuppressive therapy)
10. Physical Exam
- Vital signs: Usually normal; tachycardia and orthostasis suggest dehydration; fever typically low-grade or absent [2]
- General: Assess hydration status (mucous membranes, skin turgor, capillary refill); weight loss
- Abdomen: Diffuse mild tenderness, bloating, hyperactive bowel sounds; no peritoneal signs (if present, consider alternative diagnosis)
- Pediatric: Growth parameters (weight, height); signs of malnutrition, failure to thrive [2][4]
- Skin: Urticaria (rare) [1]
- Rectal: Watery or greasy stool on exam; no gross blood
11. Lab Studies
- Stool Giardia antigen (EIA): Sensitivity 87–100%, specificity ~100%; rapid and cost-effective [1-2]
- Stool microscopy with DFA (direct fluorescent antibody): Preferred diagnostic test per AAFP; single sample detects ~50%, three samples detect up to 90% [1]
- Multiplex stool PCR panels: Highly sensitive (92–100%) and specific (96.9–100%); detect multiple GI pathogens simultaneously [2][13]
- O&P examination: Do not order if diarrhea <7 days in immunocompetent patients without travel history (IDSA/Choosing Wisely) [1][12]
- Not helpful: Serum or fecal leukocytosis, eosinophilia [1]
- BMP/electrolytes: If dehydration suspected
- Consider: Celiac serologies (tTG-IgA) if chronic diarrhea persists despite treatment [10]
12. Imaging
- Imaging is generally not indicated for uncomplicated giardiasis
- Abdominal imaging (ultrasound or CT) may be warranted if biliary/pancreatic involvement is suspected (RUQ pain, jaundice) — rare complication [1]
- Upper endoscopy with duodenal biopsy/aspirate: Reserved for cases with high clinical suspicion but repeatedly negative stool studies [2]
13. Special Tests
- Entero-Test (string test): Alternative method for obtaining duodenal fluid when stool testing is repeatedly negative [2]
- Duodenal aspirate or biopsy: When stool specimens are negative but clinical suspicion remains high; trophozoites visualized on wet mount [2]
- D-xylose absorption test: Can assess for malabsorption in chronic cases [10]
- No validated clinical scoring system exists specifically for giardiasis severity
14. ECG
- ECG is not routinely indicated
- Consider if significant electrolyte derangements (hypokalemia, hypomagnesemia) from prolonged diarrhea/dehydration, particularly in elderly or cardiac patients
15. Assessment
- Typical presentation: Subacute onset of foul-smelling, greasy, nonbloody diarrhea with bloating, flatulence, and nausea after a 1–2 week incubation period [1-2]
- Atypical presentations: Asymptomatic carriage (common); constipation-predominant; urticaria; chronic fatigue mimicking IBS [1][11]
- Severity stratification: Most cases are mild-moderate and self-limited (2–6 weeks); severe cases with dehydration requiring hospitalization are rare [1]
- Complications to consider: Post-infectious lactose intolerance (20–40%), post-infectious IBS, reactive arthritis, growth stunting in children, chronic fatigue, fibromyalgia [2][7]
- Long-term sequelae: Emerging evidence that ~one-third of patients develop long-term extraintestinal symptoms including ocular, muscular, and metabolic complications [2][7]
16. Treatment Plan
Initial stabilization
Pharmacotherapy (preferred → alternative)
- Tinidazole 2 g PO × 1 dose (adults); 50 mg/kg × 1 dose (children ≥3 yr, max 2 g) — highest cure rate (>90%), best adherence [1][5-6]
- Nitazoxanide 500 mg PO BID × 3 days (adults); age-based dosing for children ≥1 yr — FDA-approved, available as liquid [1-2]
- Metronidazole 500 mg PO BID × 5–7 days (adults) — widely available, less efficacious, more side effects, not FDA-approved for this indication [1-2]
Treatment failure: Repeat stool testing (PCR preferred over antigen, as antigen may remain positive post-eradication); consider retreatment with a different agent or combination therapy; evaluate for reinfection source [1][12]
Asymptomatic carriers: Treat if immunocompromised, living with immunocompromised individuals, in group settings, or food handlers [1]
17. Disposition
- Discharge (vast majority): Mild-moderate symptoms, tolerating PO, no significant dehydration
- Observation/admission criteria: Severe dehydration not responsive to oral rehydration, inability to tolerate PO, significant electrolyte abnormalities, immunocompromised with severe symptoms, pediatric patients with failure to thrive [1]
- Specialist consultation triggers:
- Infectious disease: treatment failure, immunocompromised host, recurrent infections
- Gastroenterology: persistent symptoms despite treatment (consider endoscopy), suspected chronic giardiasis mimicking IBS or celiac disease [12]
- Pediatrics: growth failure, malnutrition
18. Follow Up / Return Precautions
- Follow-up timing: 5–7 days after starting treatment to assess symptom resolution; chronic giardiasis may take several months to fully resolve [1]
- Test of cure is NOT required if symptoms resolve [1][12]
- Repeat stool testing only if symptoms persist; use stool PCR or O&P (antigen assays may remain falsely positive post-treatment) [1]
- Return precautions — advise patients to return for:
- Worsening or persistent diarrhea beyond 7 days after treatment
- Signs of dehydration (dizziness, decreased urine output, dry mouth)
- Bloody stools (suggests alternative diagnosis)
- High fever
- Inability to tolerate oral fluids
- Patient counseling:
- Hand hygiene is critical to prevent transmission [2]
- Avoid alcohol during and for 72 hours after nitroimidazole therapy [6]
- Avoid untreated water; boil or filter water when camping/traveling
- Exclude from daycare/food handling until 24–48 hours after treatment initiation
- Lactose intolerance may persist for weeks after clearance — temporary dairy avoidance may help [2]
- Giardiasis is a nationally notifiable condition in the United States [1]
References
1. Common Intestinal Parasites. — Pyzocha N, Cuda A. American Family Physician. 2023.
2. Guidelines for the Prevention and Treatment of Opportunistic Infections in Children With and Exposed to HIV. — Bill G. Kapogiannis, Franklin Yates, Wei Li, et al Office of AIDS Research Advisory Council (2025). 2025.
3. Drugs for Treating Giardiasis. — Granados CE, Reveiz L, Uribe LG, Criollo CP. The Cochrane Database of Systematic Reviews. 2012.
4. Enteropathogens and Chronic Illness in Returning Travelers. — Ross AG, Olds GR, Cripps AW, Farrar JJ, McManus DP. The New England Journal of Medicine. 2013.
5. Comparative Efficacy of Drugs for Treating Giardiasis: A Systematic Update of the Literature and Network Meta-Analysis of Randomized Clinical Trials. — Ordóñez-Mena JM, McCarthy ND, Fanshawe TR. The Journal of Antimicrobial Chemotherapy. 2018.
6. FDA Drug Label. — Updated date: 2025-12-01. Food and Drug Administration.
7. Postinfectious Syndromes and Long-Term Sequelae After Giardia Infections. — Miko S, Kache PA, Imada E, Freeland AL, Haston JC. Emerging Infectious Diseases. 2025.
8. Giardia Duodenalis in Humans and Animals - Transmission and Disease. — Dixon BR. Research in Veterinary Science. 2021.
9. Giardiasis. — Wolfe MS. Clinical Microbiology Reviews. 1992.
10. Post-Travel Diarrhea. — Bradley A. Connor and Daniel T. Leung CDC Yellow Book. 2025.
11. Giardia Duodenalis: Biology and Pathogenesis. — Adam RD. Clinical Microbiology Reviews. 2021.
12. 2017 Infectious Diseases Society of America Clinical Practice Guidelines for the Diagnosis and Management of Infectious Diarrhea. — Shane AL, Mody RK, Crump JA, et al. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2017.
13. Evaluation of the Roche LightMix Gastro Parasites Multiplex PCR Assay Detecting Giardia Duodenalis, Entamoeba Histolytica, Cryptosporidia, Dientamoeba Fragilis, and Blastocystis Hominis. — Friesen J, Fuhrmann J, Kietzmann H, et al. Clinical Microbiology and Infection : The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases. 2018.